The role involves preparing and executing the launch of two new products, Avutometinib and Defactinib, specifically for low grade serous ovarian cancer.
Base: $170,000 - $200,000 annually; Bonus/Equity: Potential equity program available; Benefits: Comprehensive plan including health, dental, vision, 401k, tuition assistance
Must-have
Nice-to-have
Not specified